Primary Immunodeficiency Diseases (PIDD)
Pipeline by Development Stage
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (5)
Total enrollment: 207 patients across 5 trials
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
A Study of TAK-881 and HyQvia in Healthy Adults
Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.